CN110256373B - 一种小粒度盐酸阿考替胺结晶的制备方法 - Google Patents
一种小粒度盐酸阿考替胺结晶的制备方法 Download PDFInfo
- Publication number
- CN110256373B CN110256373B CN201910535122.3A CN201910535122A CN110256373B CN 110256373 B CN110256373 B CN 110256373B CN 201910535122 A CN201910535122 A CN 201910535122A CN 110256373 B CN110256373 B CN 110256373B
- Authority
- CN
- China
- Prior art keywords
- acotiamide hydrochloride
- solution
- acotiamide
- ethanol
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- TWHZNAUBXFZMCA-UHFFFAOYSA-N Acotiamide Chemical compound C1=C(OC)C(OC)=CC(O)=C1C(=O)NC1=NC(C(=O)NCCN(C(C)C)C(C)C)=CS1 TWHZNAUBXFZMCA-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 229950005462 acotiamide Drugs 0.000 title claims abstract description 56
- 239000013078 crystal Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000003756 stirring Methods 0.000 claims abstract description 24
- 239000002245 particle Substances 0.000 claims abstract description 16
- 238000005406 washing Methods 0.000 claims abstract description 13
- 238000010992 reflux Methods 0.000 claims abstract description 11
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000498 cooling water Substances 0.000 claims abstract description 5
- 239000002904 solvent Substances 0.000 claims abstract description 4
- 238000007664 blowing Methods 0.000 claims abstract description 3
- 238000001035 drying Methods 0.000 claims abstract description 3
- 238000001914 filtration Methods 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 19
- 239000012065 filter cake Substances 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000012046 mixed solvent Substances 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 11
- 239000002994 raw material Substances 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 2
- 239000012535 impurity Substances 0.000 description 18
- 230000001276 controlling effect Effects 0.000 description 17
- 239000008213 purified water Substances 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000012043 crude product Substances 0.000 description 9
- NPTDXIXCQCFGKC-UHFFFAOYSA-N n-[2-[di(propan-2-yl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide;trihydrate;hydrochloride Chemical group O.O.O.Cl.C1=C(OC)C(OC)=CC(O)=C1C(=O)NC1=NC(C(=O)NCCN(C(C)C)C(C)C)=CS1 NPTDXIXCQCFGKC-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000007605 air drying Methods 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 238000000967 suction filtration Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 3
- 238000010902 jet-milling Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 102000017927 CHRM1 Human genes 0.000 description 1
- 102000017926 CHRM2 Human genes 0.000 description 1
- 101150073075 Chrm1 gene Proteins 0.000 description 1
- 101150012960 Chrm2 gene Proteins 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229950003102 efonidipine Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000004684 trihydrates Chemical group 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910535122.3A CN110256373B (zh) | 2019-06-20 | 2019-06-20 | 一种小粒度盐酸阿考替胺结晶的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910535122.3A CN110256373B (zh) | 2019-06-20 | 2019-06-20 | 一种小粒度盐酸阿考替胺结晶的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110256373A CN110256373A (zh) | 2019-09-20 |
CN110256373B true CN110256373B (zh) | 2023-02-28 |
Family
ID=67919669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910535122.3A Active CN110256373B (zh) | 2019-06-20 | 2019-06-20 | 一种小粒度盐酸阿考替胺结晶的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110256373B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111454255B (zh) * | 2020-06-03 | 2022-03-18 | 迪嘉药业集团有限公司 | 一种小粒度阿齐沙坦的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103896873A (zh) * | 2013-10-23 | 2014-07-02 | 山东诚创医药技术开发有限公司 | 一种盐酸阿考替胺的精制方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2013MU04056A (zh) * | 2013-12-25 | 2015-09-25 | Cadila Healthcare Ltd |
-
2019
- 2019-06-20 CN CN201910535122.3A patent/CN110256373B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103896873A (zh) * | 2013-10-23 | 2014-07-02 | 山东诚创医药技术开发有限公司 | 一种盐酸阿考替胺的精制方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110256373A (zh) | 2019-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI597277B (zh) | 一種酪胺酸激酶抑制劑的二馬來酸鹽的第i型結晶及製備方法 | |
CN110256373B (zh) | 一种小粒度盐酸阿考替胺结晶的制备方法 | |
CN103788062A (zh) | 一种比拉斯汀晶型及其制备方法 | |
CN105753904A (zh) | 一种磷酸特地唑胺的精制方法 | |
CN106795159B (zh) | 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法 | |
CN106083963A (zh) | 一种索非布韦晶型6的制备方法 | |
CN103145735B (zh) | 一种注射用盐酸头孢甲肟化合物及其药物组合物 | |
US7138140B2 (en) | Suplatast tosilate crystals | |
CN101768105A (zh) | 丁酸氯维地平的晶型 | |
CN109438467B (zh) | 一种硫酸氢氯吡格雷ⅱ型球形结晶的制备方法 | |
CN107286183B (zh) | 一种头孢克肟的精制方法 | |
CN110590699A (zh) | 一种米拉贝隆的精制方法 | |
CN105439947A (zh) | 一种甲苯磺酸索拉非尼新晶型及其制备方法 | |
CN103709156B (zh) | 一种达沙替尼多晶型药物及其制备方法 | |
CN109020954A (zh) | 一种尼洛替尼新晶型 | |
CN110818816B (zh) | 一种舒更葡糖钠的精制结晶方法 | |
CN109369757B (zh) | 一种制备索非布韦晶型6的方法 | |
CN110526879B (zh) | 一种小粒度非布司他的结晶制备方法 | |
CN111454255B (zh) | 一种小粒度阿齐沙坦的制备方法 | |
CN113956200A (zh) | 一种粒径控制的罗沙司他原料药的结晶工艺 | |
CN105777651A (zh) | 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途 | |
CN106065016B (zh) | 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法 | |
CN105461618B (zh) | 甲磺酸洛美他派新晶型及其制备方法 | |
CN110845442B (zh) | 一种盐酸左西替利嗪化合物及其制备方法 | |
CN104086532A (zh) | 烷基胺诱导生成的右兰索拉唑多晶型及其制备方法和药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210928 Address after: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Applicant after: Dijia Pharmaceutical Group Co.,Ltd. Address before: 264205 Wendeng economic and Technological Development Zone, Weihai City, Shandong Province Applicant before: Dijia Pharmaceutical Group Co.,Ltd. Applicant before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Effective date of registration: 20210928 Address after: 264205 Wendeng economic and Technological Development Zone, Weihai City, Shandong Province Applicant after: Dijia Pharmaceutical Group Co.,Ltd. Applicant after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 266440 No.268, Tianrun Road, Wendeng economic and Technological Development Zone, Weihai City, Shandong Province Applicant before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Applicant before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
CB02 | Change of applicant information |
Address after: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Applicant after: Dijia Pharmaceutical Group Co.,Ltd. Address before: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Applicant before: Dijia Pharmaceutical Group Co.,Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method for small particle size crystallization of acotinide hydrochloride Granted publication date: 20230228 Pledgee: Weihai Branch of Shanghai Pudong Development Bank Co.,Ltd. Pledgor: Dijia Pharmaceutical Group Co.,Ltd. Registration number: Y2024980004733 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |